Drugs / AFM24
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05109442 | Nov 2021 → Mar 2025 | neoplasm | Affimed GmbH | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05099549 | Nov 2021 → Sep 2023 | colorectal neoplasm, head and neck squamous cell carcinoma, metastatic neoplasm, non-small cell lung carcinoma +1 | NKGen Biotech, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04259450 | Apr 2020 → Jul 2023 | neoplastic disease or syndrome | Affimed GmbH | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-08 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, ‘표적형 NK면역항암제’ 공동임상 미국FDA 승인 nkgenbiotechkorea.com ↗
엔케이맥스 ( 코스닥 182400) 는 아피메드 (Affimed NV) 와 공동으로 진행하는 ‘표적형 NK 면역항암제 ’ 미국 임상 1/2a 상 IND 승인을 완료했다고 1 일 밝혔다 . |
| 2021-03-31 | NKGen Biotech, Inc. | Regulatory Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors nkgenbiotech.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFM24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05109442 ↗ |
| Action | Deplete | “for the specific and efficient elimination of EGFR expressing cancer cells” NCT04259450 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05109442 ↗ |
| Target | EGFR | “anti-human EGFR” NCT04259450 ↗ |